Announcement of prospectus regarding rights issue in Active Biotech AB (publ)


The prospectus including issue documentation will be distributed to shareholders and representatives of shareholders, whose names are entered in the share register kept by VPC AB on the record date 20 May 2008.
Lund, May 15, 2008
Active Biotech AB (publ)
For further information, please contact:
Sven Andréasson
Tel: +46-46 19 20 49
Hans Kolam, CFO
Tel: +46-46 19 20 44
About Active Biotech
Active Biotech AB (OMX Nordic: ACTI) is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® for RA.
Active Biotech AB
P.O. Box 724, 220 07 Lund
Tel +46 (0)46-19 20 00
Fax +46 (0)46-19 20 50
This press release does not constitute an offer of any securities of Active Biotech. The rights issue is not directed towards shareholders or other investors in the United States of America, Canada, Japan or Australia or other countries where participation would require further prospectuses, registration or other measures than those pursuant to Swedish law. No shares, interim shares, subscription rights or other securities of Active Biotech have been or will be registered under the United States Securities Act of 1933, under the securities laws of any state of the United States or under any province law in Canada. Therefore, no new shares, interim shares, subscription rights or other securities of Active Biotech may be offered or sold, renounced, taken up or delivered in the United States or Canada except pursuant to an exemption from registration.